FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:715 February 28, 2002 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Michael K. Brawer. 327 pp., illustrated. New York, Marcel Dekker, 2001. $150. ISBN 0-8247-0555-6.

The discovery of prostate-specific antigen (PSA), a serine protease, was one of the most important accomplishments in urologic oncology in the past 15 years. In a relatively short time and in an extraordinary way, this tumor marker affected virtually all medical and surgical aspects of prostate cancer, the most prevalent malignant neoplasm in men. Today, the PSA test is an essential tool for screening, early detection, staging, definition of outcome, selection of treatment, assessment of therapeutic effects, and determination of overall prognosis.

The strengths of Prostate Specific Antigen are in its coverage of the history of PSA, the various immunoassays . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.